CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Market Closed 10-23 16:00:00 EDT

2.31

+0.07

+3.13%

盘后2.24

-0.07-3.03%

19:42 EDT

High2.33	Low2.22	Vol111.05K
Open2.23	D1 Closing2.24	Amplitude4.91%
Mkt Cap34.93M	Tradable Cap22.19M	Total Shares15.12M
T/O253.37K	T/O Rate1.16%	Tradable Shares9.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.31,"timestamp":1792785600000,"preClose":2.24,"halted":0,"volume":111048,"hourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.31,"latestTime":"19:42 EDT","volume":1346,"amount":3039.2994,"timestamp":1792798925193,"change":-0.07,"changeRate":-0.030303,"amplitude":0.030303},"delay":0,"changeRate":0.031249999999999927,"floatShares":9604400,"shares":15119100,"eps":-3.195903,"marketStatus":"Market Closed","change":0.07,"latestTime":"10-23 16:00:00 EDT","open":2.23,"high":2.33,"low":2.22,"amount":253373.12449679998,"amplitude":0.049107,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.24,"preHourTrading":{"tag":"盘前","latestPrice":2.2501,"preClose":2.24,"latestTime":"09:29 EDT","volume":1080,"amount":2444.108256,"timestamp":1792762199417,"change":0.0101,"changeRate":0.004509,"amplitude":0.03558},"postHourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.31,"latestTime":"19:42 EDT","volume":1346,"amount":3039.2994,"timestamp":1792798925193,"change":-0.07,"changeRate":-0.030303,"amplitude":0.030303},"volumeRatio":0.9033758097676404},"requestUrl":"/m/hq/s/CRVO/tweets","defaultTab":"tweets","newsList":[{"id":"2676027507","title":"Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676027507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676027507?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:40","pubTimestamp":1792406409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Legend Biotech (LEGN) and CervoMed (CRVO) with bulli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-legend-biotech-legn-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-legend-biotech-legn-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEMS","CANC","LABU","BK4137","LEGN","LU0128526141.USD","BK4581","BK4505","XLV","BK4585","LU0029874061.USD","XBI","MEDI","CRVO","BK4139","HCSG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675327595","title":"CervoMed Updates Investors with New Regulatory Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2675327595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675327595?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:30","pubTimestamp":1792009817,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has issued an update. CervoMed Inc. has made summary information on its business, clinical studies, development plans, and fin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-investors-with-new-regulatory-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-investors-with-new-regulatory-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","ISBC","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675366233","title":"Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675366233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675366233?lang=en_us&edition=fundamental","pubTime":"2026-10-14 00:55","pubTimestamp":1791910531,"startTime":"0","endTime":"0","summary":"In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on CervoMed, with a price target of $7.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-cervomed-crvo-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-cervomed-crvo-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675111352","title":"CervoMed reports encouraging biomarker data in Phase 2a trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2675111352","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675111352?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:58","pubTimestamp":1791896336,"startTime":"0","endTime":"0","summary":"The latest update is out from CervoMed ( ($CRVO) ). On October 12, 2026, CervoMed reported initial 12-week biomarker data from the open-label porti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-encouraging-biomarker-data-in-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-encouraging-biomarker-data-in-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675359971","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2675359971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675359971?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:40","pubTimestamp":1791891613,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CervoMed (CRVO), Nurix Therapeutics (NRIX) and Climb...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-377?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-377?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","LU0128526141.USD","LU0029874061.USD","XBI","HCSG","BK4137","NRIX","BK4585","BK4588","CRVO","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674721728","title":"CervoMed presents initial data from neflamapimod trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674721728","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674721728?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:40","pubTimestamp":1791805255,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced initial data showing a reduction in mean plasma levels of neurofilament light chain, or NfL, a key biomarker of neuronal ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-presents-initial-data-from-neflamapimod-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-presents-initial-data-from-neflamapimod-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872385","title":"CervoMed Says Phase 2a nfvPPA Trial of Neflamapimod Reduces Plasma NfL over 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872385","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674872385?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:30","pubTimestamp":1791804650,"startTime":"0","endTime":"0","summary":"CervoMed says Phase 2a nfvPPA trial of neflamapimod reduces plasma NfL over 12 weeksCervoMed disclosed initial Phase 2a results for neflamapimod in nonfluent variant primary progressive aphasia, prese","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDLc176dk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BCDF","BK4588","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","CRVO","SG9999014005.SGD","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4585","NDAQ","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872806","title":"CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at Isftd 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674872806?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:30","pubTimestamp":1791804600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTZ1VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674728018","title":"CervoMed - Neflamapimod Generally Well Tolerated with no New Safety Signals Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2674728018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674728018?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:30","pubTimestamp":1791804600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTZ1VD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674634872","title":"CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674634872","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674634872?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:30","pubTimestamp":1791804600,"startTime":"0","endTime":"0","summary":"On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median 24-we","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/12/3378806/0/en/cervomed-presents-initial-results-of-phase-2a-trial-of-neflamapimod-in-nonfluent-variant-primary-progressive-aphasia-nfvppa-showing-positive-effects-on-a-key-neurodegeneration-biom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","LU1481011911.USD","SGXZ23171101.USD","IE00BJJMRX11.SGD","LU0175139822.USD","LU0170899867.USD","LU2108987350.USD","BK4585","BK4588","SG9999004303.SGD","LU0731783394.SGD","LU1718418525.SGD","LU0128525689.USD","LU0982800491.AUD","LU1481011671.HKD","IE00BN29S564.USD","KBWP","LU0348723411.USD","AD","DLB","IE00BJJMRY28.SGD","IAK","BK4533","IE00BZ1G4Q59.USD","LU0070302665.USD","LU0320765489.SGD","LU0353189680.USD","LU0354030438.USD","LU0205193047.USD","LU0772969993.USD","LU0208291251.USD","LU2355687059.USD","IE00BFSS8Q28.SGD","LU1366192091.USD","IE00B775H168.HKD","IE00B7KXQ091.USD","LU1430594728.SGD","CRVO","IE00BFSS7M15.SGD","LU1035773651.USD","LU0289960550.SGD","LU0052756011.USD","PGR","LU0345774631.USD","LU0731783048.USD","LU1069347547.HKD","IE0005OL40V9.USD","IE00BKVL7J92.USD","LU0240878834.USD","LU1509826696.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861747","title":"CervoMed Updates Investor Presentation and Disclosure Practices","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861747?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:29","pubTimestamp":1791577772,"startTime":"0","endTime":"0","summary":"The latest announcement is out from CervoMed ( ($CRVO) ). CervoMed announced that summary information on its business, clinical programs, developme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-investor-presentation-and-disclosure-practices?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-investor-presentation-and-disclosure-practices?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704074","title":"CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704074?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:36","pubTimestamp":1791200160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759081","title":"Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759081","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759081?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851504,"startTime":"0","endTime":"0","summary":"Insiders who purchased US$3.46m worth of CervoMed Inc. ( NASDAQ:CRVO ) shares over the past year recouped some of their...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvo/cervomed/news/hopeful-week-for-insiders-who-bought-us346m-of-cervomed-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvo/cervomed/news/hopeful-week-for-insiders-who-bought-us346m-of-cervomed-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215002","title":"Canaccord Genuity Sticks to Its Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671215002?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:56","pubTimestamp":1790679371,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on CervoMed today and set a price target of $18.00. Kulkarni covers the Healthcar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671435268","title":"CervoMed Advances Neflamapimod Tablet and Dosing Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671435268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671435268?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:26","pubTimestamp":1790630803,"startTime":"0","endTime":"0","summary":"An announcement from CervoMed ( ($CRVO) ) is now available. On September 28, 2026, CervoMed reported new pharmacokinetic, regulatory, and manufactu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-tablet-and-dosing-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-tablet-and-dosing-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256372","title":"CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256372","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256372?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:45","pubTimestamp":1790606737,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on CervoMed, with a price target of $12.00. Boris Peaker has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-improved-dosing-safety-margin-and-cmc-profile-bolster-confidence-in-100-mg-bid-regimen-buy-rating-and-12-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-improved-dosing-safety-margin-and-cmc-profile-bolster-confidence-in-100-mg-bid-regimen-buy-rating-and-12-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253220","title":"CervoMed neflamapimod update removes key overhang, says Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670253220?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:05","pubTimestamp":1790604345,"startTime":"0","endTime":"0","summary":"Jones analyst Boris Peaker says CervoMed (CRVO) announced this morning that the FDA removed neflamapimod’s prior drug exposure limit, allowing the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-neflamapimod-update-removes-key-overhang-says-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-neflamapimod-update-removes-key-overhang-says-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","CRVO","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670304232","title":"CervoMed announces PK results with new neflamapimod oral tablet formula","url":"https://stock-news.laohu8.com/highlight/detail?id=2670304232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670304232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:55","pubTimestamp":1790596521,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced pharmacokinetic, PK, regulatory, and manufacturing advances that enable a higher-dose, twice-daily oral regimen of neflam...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-announces-pk-results-with-new-neflamapimod-oral-tablet-formula-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-announces-pk-results-with-new-neflamapimod-oral-tablet-formula-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","EES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234810","title":"CervoMed Plans Neflamapimod 100 Mg Twice-Daily Regimen for Future Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234810?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:32","pubTimestamp":1790595135,"startTime":"0","endTime":"0","summary":"CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trialsCervoMed disclosed Phase 1 study results for a new neflamapimod 50 mg tablet, positioning it for twice-daily dosing.The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbTjnxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BCDF","BK4585","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","CRVO","BK4588","NDAQ","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670702231","title":"CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit","url":"https://stock-news.laohu8.com/highlight/detail?id=2670702231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670702231?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUA5L0B70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":0.0312},{"period":"1month","weight":-0.0797},{"period":"3month","weight":-0.1316},{"period":"6month","weight":-0.4046},{"period":"1year","weight":-0.6737},{"period":"ytd","weight":-0.7076}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.023389},{"month":2,"riseRate":0.5,"avgChangeRate":0.085839},{"month":3,"riseRate":0.5,"avgChangeRate":0.326048},{"month":4,"riseRate":0.3,"avgChangeRate":-0.063988},{"month":5,"riseRate":0.4,"avgChangeRate":0.116259},{"month":6,"riseRate":0.1,"avgChangeRate":-0.109707},{"month":7,"riseRate":0.2,"avgChangeRate":-0.086929},{"month":8,"riseRate":0.7,"avgChangeRate":0.070615},{"month":9,"riseRate":0.2,"avgChangeRate":-0.093005},{"month":10,"riseRate":0.1,"avgChangeRate":-0.057627},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.206034}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction